+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Acute Myeloid Leukemia Drug"

From
From
From
Relapsed/refractory acute myeloid leukemia (AML) - Pipeline Insight, 2024 - Product Thumbnail Image

Relapsed/refractory acute myeloid leukemia (AML) - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 180 Pages
  • Global
From
Acute Myelogenous Leukemia (AML) - Pipeline Insight, 2024 - Product Thumbnail Image

Acute Myelogenous Leukemia (AML) - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Acute Myeloid Leukemia (AML) - Epidemiology Forecast to 2032 - Product Thumbnail Image

Acute Myeloid Leukemia (AML) - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
From
Acute Myelogenous Leukemia (AML) - Epidemiology Forecast - 2032 - Product Thumbnail Image

Acute Myelogenous Leukemia (AML) - Epidemiology Forecast - 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
From
From
From
Acute Myeloid Leukemia - Epidemiology Forecast to 2029 - Product Thumbnail Image

Acute Myeloid Leukemia - Epidemiology Forecast to 2029

  • Report
  • June 2020
  • 37 Pages
  • Global
From
Loading Indicator

Acute Myeloid Leukemia (AML) is a type of cancer that affects the blood and bone marrow. It is the most common type of acute leukemia in adults. Treatment for AML typically involves chemotherapy, radiation therapy, and stem cell transplantation. Drugs used to treat AML include cytarabine, daunorubicin, and idarubicin. These drugs are used to kill cancer cells, reduce the size of tumors, and reduce the risk of relapse. Other drugs used to treat AML include decitabine, gemtuzumab ozogamicin, and venetoclax. These drugs are used to target specific genetic mutations that are associated with AML. The AML drug market is highly competitive, with many companies offering a variety of treatments. Some of the major players in the market include Novartis, Pfizer, Celgene, Bristol-Myers Squibb, and Merck. Other companies in the market include AbbVie, AstraZeneca, Johnson & Johnson, and Sanofi. Show Less Read more